GlassScriptPhysician profile
Adelya Minulina
NPI 1629730965
$6,898.78
in general payments reported to CMS, 2019-2025
41 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $1,267 · 2023: $1,768 · 2024: $1,518 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.05 |
| Education | $119.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $758.34 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Amphastar Pharmaceuticals, INC. | $597.54 | 2024-2025 | |
| Incyte Corporation | $489.87 | 2024-2025 | Opzelura |
| Abbvie INC. | $458.46 | 2023-2025 | |
| Mannkind Corporation | $372.59 | 2022-2024 | Afrezza, V-Go |
| E.R. Squibb & Sons, L.L.C. | $339.36 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $316.32 | 2024-2025 | |
| Dermavant Sciences, INC. | $293.51 | 2022-2023 | Vtama |
| Ucb, INC. | $288.90 | 2023-2025 | Bimzelx, Cimzia |
| Cequr Corporation | $276.13 | 2022-2024 | Cequr Simplicity |
| Novo Nordisk INC | $258.88 | 2022-2024 | Wegovy, Saxenda |
| Regeneron Healthcare Solutions, INC. | $249.72 | 2023-2025 | Dupixent |
| Pfizer INC. | $239.38 | 2023-2025 | |
| Amgen INC. | $207.34 | 2021-2025 | Otezla, Prolia, Evenity |
| Organon LLC | $189.33 | 2025 | Vtama |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelya Minulina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.